259 related articles for article (PubMed ID: 25943747)
1. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
[TBL] [Abstract][Full Text] [Related]
2. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
Camerini A; Banna GL; Cinieri S; Pezzuto A; Mencoboni M; Rosetti F; Figueiredo A; Rizzo P; Ricci A; Langenhoven L; Santo A; Addeo A; Amoroso D; Barata F
Clin Transl Oncol; 2019 Jun; 21(6):790-795. PubMed ID: 30448956
[TBL] [Abstract][Full Text] [Related]
3. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
Mencoboni M; Filiberti RA; Taveggia P; Del Corso L; Del Conte A; Covesnon MG; Puccetti C; Donati S; Auriati L; Amoroso D; Camerini A
Anticancer Res; 2017 Jun; 37(6):3189-3194. PubMed ID: 28551663
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and Toxicity of Metronomic Oral Vinorelbinen in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments].
Yao S; Gu Y; Zhang Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):737-740. PubMed ID: 29167002
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.
Kontopodis E; Hatzidaki D; Varthalitis I; Kentepozidis N; Giassas S; Pantazopoulos N; Vardakis N; Rovithi M; Georgoulias V; Agelaki S
J Chemother; 2013 Feb; 25(1):49-55. PubMed ID: 23433445
[TBL] [Abstract][Full Text] [Related]
7. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
Tan EH; Tan DS; Li WY; Haaland B; Ang MK; Chau NM; Toh CK; Tan IB; Koh TS; Thng CH; Chowbay B; Hui KM; Lim WT; Ng QS
Lung Cancer; 2015 Jun; 88(3):289-96. PubMed ID: 25896396
[TBL] [Abstract][Full Text] [Related]
8. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
[TBL] [Abstract][Full Text] [Related]
9. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.
Camerini A; Valsuani C; Mazzoni F; Siclari O; Puccetti C; Donati S; Rondini M; Tartarelli G; Puccinelli P; Di Costanzo F; Amoroso D
Ann Oncol; 2010 Jun; 21(6):1290-1295. PubMed ID: 19914959
[TBL] [Abstract][Full Text] [Related]
13. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
[TBL] [Abstract][Full Text] [Related]
14. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
Barlesi F; Imbs DC; Tomasini P; Greillier L; Galloux M; Testot-Ferry A; Garcia M; Elharrar X; Pelletier A; André N; Mascaux C; Lacarelle B; Cheikh RE; Serre R; Ciccolini J; Barbolosi D
Oncotarget; 2017 Jul; 8(29):47161-47166. PubMed ID: 28525370
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.
Gridelli C; Manegold C; Mali P; Reck M; Portalone L; Castelnau O; Stahel R; Betticher D; Pless M; Pons JT; Aubert D; Burillon JP; Parlier Y; De Marinis F
Eur J Cancer; 2004 Nov; 40(16):2424-31. PubMed ID: 15519515
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
17. Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study.
Carabante-Ocón F; Cobo-Dols M; Benavides-Orgaz M; Gil-Calle S; Alés-Díaz I; Bretón-García JJ; Villar-Chamorro E; Montesa-Pino A; Alcalde-García J; Gutiérrez-Calderón V
Clin Lung Cancer; 2005 Sep; 7(2):121-6. PubMed ID: 16179099
[TBL] [Abstract][Full Text] [Related]
18. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H
J Clin Oncol; 2006 Feb; 24(4):688-94. PubMed ID: 16446342
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
